Skip to Content
Morningstar

WisdomTree BioRevolution ETF WDNA

Morningstar Medalist Rating
Medalist Rating as of | See WisdomTree Investment Hub

Morningstar’s Analysis WDNA

Will WDNA outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Process Pillar

The Process Pillar is our assessment of how sensible, clearly defined, and repeatable WDNA’s performance objective and investment process is for both security selection and portfolio construction.

People Pillar

The People Pillar is our evaluation of the WDNA management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

Parent Pillar

The Parent Pillar is our rating of WDNA’s parent organization’s priorities and whether they’re in line with investors’ interests.

WisdomTree BioRevolution ETF’s management team is rated Average, but a solid investment process still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the lowest fee quintile among peers.

by Morningstar Manager Research
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings WDNA

More WDNA Holdings
  • Current Portfolio Date
  • Equity Holdings 93
  • Bond Holdings 0
  • Other Holdings 0
  • % Assets in Top 10 Holdings 17.3
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Twist Bioscience Corp

2.42
58,799
Healthcare

Editas Medicine Inc

1.86
45,050
Healthcare

BridgeBio Pharma Inc

1.83
44,413
Healthcare

Blueprint Medicines Corp

1.79
43,485
Healthcare

Eli Lilly and Co

1.68
40,838
Healthcare

CRISPR Therapeutics AG

1.67
40,625
Healthcare

Ionis Pharmaceuticals Inc

1.51
36,761
Healthcare

Iovance Biotherapeutics Inc

1.51
36,755
Healthcare

Vericel Corp

1.50
36,540
Healthcare

Veracyte Inc

1.48
35,842
Healthcare